Two Sidley representations were recognized at the LMG Life Sciences Awards 2023. Sidley’s representation of Akeso in its US$5 billion licensing and collaboration agreement with Summit Therapeutics to develop a bispecific antibody received the “Impact Deal of the Year” award. Further, the Amgen v. Sandoz case was awarded “Patent Impact Case of the Year.”
Sidley represented Akeso, Inc. in a high-profile US$5 billion collaboration and licensing agreement with Summit Therapeutics, Inc. to out-license its breakthrough bispecific antibody, ivonescimab, for development and commercialization in the U.S., Canada, Europe, and Japan. Ivonescimab is a novel, potential first-in-class bispecific antibody independently developed by Akeso. The deal, one of the largest of its kind in 2022 and in recent years, is demonstrative of Sidley’s ability to handle clients’ most significant global life sciences transactions.
On April 19, 2023, Sidley won a victory for Amgen Inc. when the U.S. Court of Appeals for the Federal Circuit affirmed the judgment of the U.S. District Court for the District of New Jersey in a patent infringement lawsuit brought by Amgen against Sandoz Inc. and Zydus Pharmaceuticals (USA), Inc. The precedential ruling affirmed the permanent injunction entered by the district court prohibiting Sandoz and Zydus from making, using, selling, offering to sell, or importing each of their generic versions of Otezla® — Amgen’s oral medication for the treatment of psoriasis — until the expiration in February 2028 of Amgen’s patent covering the active ingredient in Otezla®. Steven Horowitz (Chicago) led the Sidley team and argued the appeal. The team included Joshua Fougere (Washington, D.C.) and Sue Wang (San Francisco), as well as co-counsel from Covington & Burling LLP.
The annual LMG Life Sciences Americas Awards identifies the leading North American law firms and lawyers in the life sciences industry.
Sidley represented Akeso, Inc. in a high-profile US$5 billion collaboration and licensing agreement with Summit Therapeutics, Inc. to out-license its breakthrough bispecific antibody, ivonescimab, for development and commercialization in the U.S., Canada, Europe, and Japan. Ivonescimab is a novel, potential first-in-class bispecific antibody independently developed by Akeso. The deal, one of the largest of its kind in 2022 and in recent years, is demonstrative of Sidley’s ability to handle clients’ most significant global life sciences transactions.
On April 19, 2023, Sidley won a victory for Amgen Inc. when the U.S. Court of Appeals for the Federal Circuit affirmed the judgment of the U.S. District Court for the District of New Jersey in a patent infringement lawsuit brought by Amgen against Sandoz Inc. and Zydus Pharmaceuticals (USA), Inc. The precedential ruling affirmed the permanent injunction entered by the district court prohibiting Sandoz and Zydus from making, using, selling, offering to sell, or importing each of their generic versions of Otezla® — Amgen’s oral medication for the treatment of psoriasis — until the expiration in February 2028 of Amgen’s patent covering the active ingredient in Otezla®. Steven Horowitz (Chicago) led the Sidley team and argued the appeal. The team included Joshua Fougere (Washington, D.C.) and Sue Wang (San Francisco), as well as co-counsel from Covington & Burling LLP.
The annual LMG Life Sciences Americas Awards identifies the leading North American law firms and lawyers in the life sciences industry.
